Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 11Brain Neoplasms 7Triple Negative Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Unresectable Locally Recurrent Breast Cancer 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Inflammatory Breast Neoplasms 1HER2-negative Breast Cancer 1HER2-low Hormone Receptor Positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1HER2 Overexpression 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

spartalizumab 2durvalumab 2zanidatamab 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1pembrolizumab 1obinutuzumab 1naptumomab estafenatox 1Trastuzumab 1Polymerase Chain Reaction 1Nivolumab 1Mass Spectrometry 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Gemcitabine 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × trastuzumab deruxtecan × Breast × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡